Skip to main content

We've saved some files called cookies on your device. These cookies are:

  • essential for the site to work
  • to help improve our website by collecting and reporting information on how you use it

We would also like to save some cookies to help tailor communications.

BETA
You're viewing an updated version of this service - your feedback will help us to improve it.

03 Contract Award Notice - Incomplete Procedure

Tender for the Operating Lease of a Surface Plasmon Resonance (SPR) Instrument

  • First published: 09 November 2020
  • Last modified: 09 November 2020
  • Version: N/A
  •  

  • This file may not be fully accessible.

  •  

Information icon

The buyer is not using this website to administer the notice.

To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Contents

Summary

OCID:
ocds-kuma6s-099500
Published by:
Swansea University
Authority ID:
AA0345
Publication date:
09 November 2020
Deadline date:
-
Notice type:
03 Contract Award Notice - Incomplete Procedure
Has documents:
No
Has SPD:
No
Has Carbon Reduction Plan:
N/A

Abstract

the Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6m GB project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is looking to develop advanced drug technologies for the treatment of ovarian cancer. Building on RBGO success in recent years, CEAT is a collaboration of 6 industrial partners working towards the prevention and treatment of ovarian cancer by embedding enabling technologies and innovation into pre-clinical drug development pipelines for: The advancement of novel epigenetic drugs using cross cutting technology approaches. The development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments The generation of novel ADCs effective against ovarian cancer For antibody development, the SPR detection instrument will be used for early-stage screening of hybridoma/bispecific libraries, to monitor expression and triage antibodies based on binding affinity, profiling binding specificity and providing detailed binding kinetics and affinity to characterisation. CPV: 38510000, 33100000, 38000000, 38434540, 39162000, 38510000.

Full notice text

Contract award notice

Results of the procurement procedure

Section I: Contracting entity

I.1) Name and addresses

Swansea University

Procurement - Finance, Swansea University, Singleton Park

Swansea

SA2 8PP

UK

Telephone: +44 1792295890

E-mail: procurement@swansea.ac.uk

NUTS: UKL18

Internet address(es)

Main address: www.swansea.ac.uk

Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0345

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Education

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Tender for the Operating Lease of a Surface Plasmon Resonance (SPR) Instrument

Reference number: SU122(20)

II.1.2) Main CPV code

38510000

 

II.1.3) Type of contract

Supplies

II.1.4) Short description

the Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6m GB project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is looking to develop advanced drug technologies for the treatment of ovarian cancer. Building on RBGO success in recent years, CEAT is a collaboration of 6 industrial partners working towards the prevention and treatment of ovarian cancer by embedding enabling technologies and innovation into pre-clinical drug development pipelines for:

The advancement of novel epigenetic drugs using cross cutting technology approaches.

The development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments

The generation of novel ADCs effective against ovarian cancer

For antibody development, the SPR detection instrument will be used for early-stage screening of hybridoma/bispecific libraries, to monitor expression and triage antibodies based on binding affinity, profiling binding specificity and providing detailed binding kinetics and affinity to characterisation.

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

33100000

38000000

38434540

39162000

38510000

II.2.3) Place of performance

NUTS code:

UKL18


Main site or place of performance:

Swansea University Singleton campus

II.2.4) Description of the procurement

The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6m GB project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is looking to develop advanced drug technologies for the treatment of ovarian cancer. Building on RBGO success in recent years, CEAT is a collaboration of 6 industrial partners working towards the prevention and treatment of ovarian cancer by embedding enabling technologies and innovation into pre-clinical drug development pipelines for:

The advancement of novel epigenetic drugs using cross cutting technology approaches.

The development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments

The generation of novel ADCs effective against ovarian cancer.

For antibody development, the SPR detection instrument will be used for early-stage screening of hybridoma/bispecific libraries, to monitor expression and triage antibodies based on binding affinity, profiling binding specificity and providing detailed binding kinetics and affinity to characterisation.

II.2.5) Award criteria

Quality criterion: as per procurement documents / Weighting: 100

Price / Weighting:  0

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

II.2.14) Additional information

The funding for this purchase covers only the Lease not Purchase of the Equipment. Therefore we are seeking a supplier who can Lease the Equipment detailed within the Tender Specification for the duration of the CEAT project

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2020/S 046-109649

Section V: Award of contract

Contract No: SU122(20)

A contract/lot is awarded: No

V.1 Information on non-award

The contract/lot is not awarded

Other reasons (discontinuation of procedure)

Section VI: Complementary information

VI.3) Additional information

The funding for this equipment is for the Lease not Purchase of the detailed equipment, for the duration of the CEAT project up to 31st October 2021

(WA Ref:105502)

VI.4) Procedures for review

VI.4.1) Review body

High Court

Royal Courts of Justice, The Strand

London

WC2A 2LL

UK

Telephone: +44 2079477501

VI.5) Date of dispatch of this notice

06/11/2020

Coding

Commodity categories

ID Title Parent category
38434540 Biomedical equipment Analysers
39162000 Educational equipment School furniture
38000000 Laboratory, optical and precision equipments (excl. glasses) Technology and Equipment
33100000 Medical equipments Medical equipments, pharmaceuticals and personal care products
38510000 Microscopes Checking and testing apparatus

Delivery locations

ID Description
1017 Bridgend and Neath Port Talbot
1018 Swansea

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID Description
There are no alert restrictions for this notice.

Document family

Notice details
Publication date:
04 March 2020
Deadline date:
05 November 2020 00:00
Notice type:
02 Contract Notice
Authority name:
Swansea University
Publication date:
09 November 2020
Notice type:
03 Contract Award Notice - Incomplete Procedure
Authority name:
Swansea University

About the buyer

Main contact:
procurement@swansea.ac.uk
Admin contact:
N/a
Technical contact:
N/a
Other contact:
N/a

Further information

Date Details
No further information has been uploaded.

0800 222 9004

Lines are open 8:30am to 5pm Monday to Friday.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.